Table 1 Demographic and clinical data of reported cases of DSF after gastrectomy for malignant disease
Author/Year | Study period | Study type | Patients with DSF, n | Neoadjuvant chemotherapy, n | AJCC TNM stage | DSF diagnosis after operation, median days (range) | DSF output, median ml/day (range) | DSF-related complications |
|---|---|---|---|---|---|---|---|---|
Garden et al./1988 [9] | 1979–1985 | RS | 5 | NA | NA | NA | 1130 (120–2500)a | NA |
Bloch et al./1989 [10] | 1989 | Case | 1 | 0 | I 1 | NA | NA | NA |
Kyzer et al./1997 [11] | 1991–1994 | RS | 2 | NA | NA | NA | NA | Sepsis (50%) |
Wong et al./2000 [12] | 1993–1997 | RS | 1 | NA | NA | NA | 210 | Abdominal abscess |
Oh et al./2009 [13] | 1987–2004 | RS | 5 | NA | NA | NA | NA | Sepsis (100%) |
Lee et al./2009 [14] | 2009 | Case | 1 | 0 | I 1 | 7 | NA | Abdominal abscess |
Cozzaglio et al./2010 [5] | 1991–2006 | RS | 68 | 2 | NA | 7 (0–22) | 290 (40–2200) | Abdominal abscess (38%), Wound infection (28%), Sepsis (26%), Central line infection (15%), Pneumonia (13%), Acute renal failure (10%), Colonic fistula (7%), Pancreatic fistula (6%), Acute pancreatitis (6%), Intraabdominal bleeding (6%), Abdominal wall necrosis (4%), Pulmonary embolism (3%), Jejunal fistula (3%), Roux-en-Y syndrome (3%), Esophagojejunal fistula (3%), Heart failure (3%), Others (11%) |
Hur et al./2010 [15] | 2005–2007 | RS | 4 | NA | NA | NA | NA | Abdominal abscess (100%) |
Cozzaglio et al./2011 [16] | 2005–2010 | RS | 6 | NA | NA | 6 (2–22) | 500 (300–1000) | Sepsis (50%) |
Curcio et al./2012 [17] | 2012 | Case | 1 | 0 | I 1 | NA | NA | Abdominal abscess |
Oh et al./2013 [18] | 2005–2011 | RS | 10 | NA | NA | 10 (6–20) | NA | Abdominal fluids or abcess (100%) |
Blouhos et al./2013 [19] | 2013 | Case | 1 | NA | IV 1 | 1 | NA | Sepsis, Intra-abdominal bleeding |
Vasiliadis et al./2014Â [20] | 2014 | Case | 1 | NA | III 1 | NA | NA | Dehydration and electrolyte disorders |
Kim et al./2014 [21] | 2002–2012 | RS | 13 | NA | I 8, II 4, III 1 | 5 (1–12) | NA | NA |
Orsenigo et al./2014 [3] | 1987–2012 | RS | 32 | 0 | I 7, II 9, III 9, IV 7 | 6.6 ± 4.7a | 246 ± 266a | Sepsis (75%), Abdominal abscess (69%), Pneumonia (34%), Surgical site infection (28%), Intra-abdominal bleeding (22%), Acute renal failure (16%), Colonic fistula (12%), Gastro-jejunal anastomosis leakage (6%), Central line infection (6%), Pneumothorax (6%) |
Cornejo et al./2016 [22] | 1997–2014 | RS | 13 | NA | I 4, II 5, III 2, IV 2 | 5 (3–7)a | NA | Sepsis (23%), Major Hematemesis (15%), Evisceration (8%), Abdominal abscess (8%) |
Cozzaglio et al./2016 [4] | 1990–2011 | RS | 75 | 3 | NA | 6 (2–11) | 300 (100–750) | Abdominal abscess (70.7%); Sepsis (61.3%); Pneumonia (44%); Surgical site infection (38.7%); Digestive fistulas (29.3%); 2Acute renal failure (28%); Intra-abdominal bleeding (24%); Central line infection (17.3%); Acute pancreatitis (9.3%); Abdominal wall necrosis (8%); Others (21.3%) |
Ali et al./2016 [7] | 2010–2014 | RS | 24 | NA | I 8, II 9, III 6, IV 1 | 8.5 (1–20) | NA | Pneumonia (20.8%), Sepsis (8.3%), Intra-abdominal bleeding (8.3%), Surgical site infection (8.3%), Deep vein thrombosis (8.3%) |
Paik et al./2016 [6] | 2008–2013 | RS | 16 | NA | NA | 6.5 (1–13) | NA | NA |
Ramos et al./2018 [2] | 2009–2017 | RS | 15 | 2 | I/II 9, III/IV 6 | 9 (1–75) | NA | NA |